Torii Pharmaceutical (TRXPF) 29.0000 $TRXPF
ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
GlobeNewswire - Mon Jun 16, 2:09AM CDT
Based on the available data, Torii expects to submit a registration application to the authorities within the next six-to-ten months.
ALK's Partner for Japan Reports Positive Trial Results for House Dust Mite SLIT-tablet
GlobeNewswire - Mon Mar 10, 2:10AM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. (TSE: 4551), has reported positive results from its Phase II/III trial into ALK's sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever).
Cedar Pollen Allergy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3sxtk/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Cedar Pollen Allergy. - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cedar Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cedar Pollen Allergy Overview Therapeutics Development Cedar Pollen Allergy - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Cedar Pollen Allergy - Therapeutics Assessment Drug Profiles TO-194SL - Drug Profile TAC-201 - Drug Profile Cry J1-galactomannan Conjugate - Drug Profile JRC-LAMP Vax - Drug Profile TO-206 - Drug Profile Pollinex Quattro Japanese Cedar - Drug Profile RGI-1001 - Drug Profile Japanese Cedar Pollen Tablet - Drug Profile Japanese Cedar Hypoallergenic Vaccine - Drug Profile AllerJ - Drug Profile Cedar Pollen Vaccine - Drug Profile Vaccine For Japanese Cedar Pollen Allergy - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Taiho Pharmaceutical Co., Ltd. Allergy Therapeutics plc Stallergenes S.A. Torii Pharmaceutical Co., Ltd. Anergis SA REGiMMUNE Corporation Immunomic Therapeutics, Inc. Biomay AG Adiga Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/f3...dar_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Keryx Biopharmaceuticals wins marketing approval in Japan of Ferric Citrate, triggering milestone payment
M2 - Mon Jan 20, 5:50AM CST
US-based pharmaceutical company Keryx Biopharmaceuticals Inc (KERX) said on Friday that its Japanese partner, Japan Tobacco Inc (JT), has received manufacturing and marketing approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare.
Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan
PR Newswire Europe - Fri Jan 17, 7:01AM CST
- Marketing Approval Triggers Milestone Payment to Keryx
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
Cedar Pollen Allergy - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wj83qr/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understand
House Dust Mite Allergy - Pipeline Review, H1 2013 Available Now
M2 - Tue Jun 04, 11:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdngvg/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for House Dust Mite Allergy. - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Holdings Ltd. - Genetic Immunity, LLC - ANERGIS SA - Bial - Portela & Ca, S.A. - Biomay AG For more information visit http://www.researchandmarkets.com/research/sd..._dust_mite About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
GlobeNewswire - Mon Jun 16, 2:09AM CDT
Based on the available data, Torii expects to submit a registration application to the authorities within the next six-to-ten months.
ALK's Partner for Japan Reports Positive Trial Results for House Dust Mite SLIT-tablet
GlobeNewswire - Mon Mar 10, 2:10AM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. (TSE: 4551), has reported positive results from its Phase II/III trial into ALK's sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever). Cedar Pollen Allergy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3sxtk/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Cedar Pollen Allergy. - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cedar Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cedar Pollen Allergy Overview Therapeutics Development Cedar Pollen Allergy - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Cedar Pollen Allergy - Therapeutics Assessment Drug Profiles TO-194SL - Drug Profile TAC-201 - Drug Profile Cry J1-galactomannan Conjugate - Drug Profile JRC-LAMP Vax - Drug Profile TO-206 - Drug Profile Pollinex Quattro Japanese Cedar - Drug Profile RGI-1001 - Drug Profile Japanese Cedar Pollen Tablet - Drug Profile Japanese Cedar Hypoallergenic Vaccine - Drug Profile AllerJ - Drug Profile Cedar Pollen Vaccine - Drug Profile Vaccine For Japanese Cedar Pollen Allergy - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Taiho Pharmaceutical Co., Ltd. Allergy Therapeutics plc Stallergenes S.A. Torii Pharmaceutical Co., Ltd. Anergis SA REGiMMUNE Corporation Immunomic Therapeutics, Inc. Biomay AG Adiga Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/f3...dar_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Keryx Biopharmaceuticals wins marketing approval in Japan of Ferric Citrate, triggering milestone payment
M2 - Mon Jan 20, 5:50AM CST
US-based pharmaceutical company Keryx Biopharmaceuticals Inc (KERX) said on Friday that its Japanese partner, Japan Tobacco Inc (JT), has received manufacturing and marketing approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare.
Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan
PR Newswire Europe - Fri Jan 17, 7:01AM CST
- Marketing Approval Triggers Milestone Payment to Keryx
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
Cedar Pollen Allergy - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wj83qr/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understand
House Dust Mite Allergy - Pipeline Review, H1 2013 Available Now
M2 - Tue Jun 04, 11:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sdngvg/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for House Dust Mite Allergy. - A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - DBV Technologies - Stallergenes S.A. - Torii Pharmaceutical Co., Ltd. - Circassia Holdings Ltd. - Genetic Immunity, LLC - ANERGIS SA - Bial - Portela & Ca, S.A. - Biomay AG For more information visit http://www.researchandmarkets.com/research/sd..._dust_mite About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
